NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $34.00 price target on the stock.

NRXP has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Ascendiant Capital Markets restated a “buy” rating and set a $48.00 price objective (up previously from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Finally, Zacks Research cut shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $36.75.

NRx Pharmaceuticals Stock Performance

NRXP opened at $1.84 on Tuesday. NRx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $3.84. The company’s 50 day simple moving average is $2.18 and its 200 day simple moving average is $2.55. The stock has a market capitalization of $58.64 million, a PE ratio of -0.78 and a beta of 1.91.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in NRXP. Anson Funds Management LP raised its holdings in shares of NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after purchasing an additional 1,018,853 shares during the last quarter. State Street Corp boosted its holdings in shares of NRx Pharmaceuticals by 14.0% in the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after purchasing an additional 10,700 shares in the last quarter. Commonwealth Equity Services LLC bought a new position in NRx Pharmaceuticals during the fourth quarter valued at approximately $994,000. Geode Capital Management LLC lifted its stake in NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after purchasing an additional 33,004 shares during the last quarter. Finally, Bleakley Financial Group LLC purchased a new stake in NRx Pharmaceuticals during the 4th quarter valued at about $318,000. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.